Sep 16, 2025
Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
Sep 11, 2025
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
Sep 10, 2025
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
Aug 05, 2025
Lucid Diagnostics to Participate in Upcoming Investor Conferences
Apr 24, 2025
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD
Mar 24, 2025
Lucid Diagnostics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
Mar 20, 2025
Lucid Diagnostics Announces Updated National Comprehensive Cancer Network® (NCCN) Guidelines Now Include Esophageal Precancer Screening
Mar 18, 2025
Lucid Diagnostics' ENVET-BE Clinical Utility Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Mar 13, 2025
Lucid Diagnostics Secures First Positive Commercial Insurance Coverage Policy for its EsoGuard® Esophageal DNA Test
Mar 10, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 24, 2025
Mar 05, 2025
Lucid Diagnostics Announces Closing of $15.3 Million Registered Direct Offering
Mar 04, 2025
Lucid Diagnostics Announces $15.3 Million Registered Direct Offering
Feb 20, 2025
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health
Feb 06, 2025
Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Jan 13, 2025
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume
Dec 23, 2024
Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
Nov 20, 2024
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
Nov 13, 2024
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results
Oct 15, 2024
Lucid Diagnostics Receives Notice of Allowance for Key Patent Underlying Its EsoGuard Esophageal DNA Test
Oct 08, 2024
Lucid Diagnostics to Join Global Medtech Leaders at The MedTech Conference 2024